ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. It offers Derazantinib (ARQ 087), a multi-kinase inhibitor of the fibroblast growth factor receptor (FGFR) family that is in a registration trial in intrahepatic cholangiocarcinoma with FGFR2 fusions. The company's clinical-stage products include Miransertib (ARQ 092), an inhibitor of the AKT serine/threonine kinase in Phase 1/2 clinical trial in rare Overgrowth Diseases, Phase 1 clinical trial in the rare disease, and in Phase 1b in oncology in combination with the hormonal therapy and anastrozole; ARQ 751, a next-generation inhibitor of AKT that is in Phase I clinical trial for solid tumors harboring the AKT1 or PI3K mutation; ARQ 761, a ß-lapachone analog evaluated as a promoter of NQO1-mediated programmed cancer cell death which is in Phase 1/2 clinical trial in multiple oncology; and ARQ 531, an orally bioavailable, potent and reversible inhibitor of wild type and C481S-mutant Bruton's tyrosine kinase that is in Phase 1 for B-cell malignancies refractory to other therapeutic options. It has collaboration agreement with Roivant Sciences Ltd. to develop derazantinib, a pan-FGFR inhibitor. ArQule, Inc. was founded in 1993 and is headquartered in Burlington, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:ARQL
CUSIP04269E10
Phone781-994-0300
Debt
Debt-to-Equity Ratio0.54
Current Ratio5.99
Quick Ratio5.99
Price-To-Earnings
Trailing P/E Ratio-14.56
Forward P/E Ratio-47.33
P/E GrowthN/A
Sales & Book Value
Annual Sales$4.71 million
Price / Sales131.23
Cash FlowN/A
Price / CashN/A
Book Value$0.16 per share
Price / Book35.50
Profitability
EPS (Most Recent Fiscal Year)($0.39)
Net Income$-29,200,000.00
Net MarginsN/A
Return on Equity-110.58%
Return on Assets-36.66%
Miscellaneous
Employees32
Outstanding Shares108,820,000
Market Cap$682.28 million
ArQule (NASDAQ:ARQL) Frequently Asked Questions
What is ArQule's stock symbol?
ArQule trades on the NASDAQ under the ticker symbol "ARQL."
How were ArQule's earnings last quarter?
ArQule, Inc. (NASDAQ:ARQL) issued its earnings results on Wednesday, August, 1st. The biotechnology company reported $0.05 EPS for the quarter, beating the Zacks' consensus estimate of $0.03 by $0.02. The biotechnology company earned $13.71 million during the quarter, compared to analyst estimates of $7.70 million. During the same quarter last year, the company earned ($0.12) earnings per share. View ArQule's Earnings History.
When is ArQule's next earnings date?
What price target have analysts set for ARQL?
5 Wall Street analysts have issued 12-month target prices for ArQule's stock. Their predictions range from $6.00 to $7.00. On average, they anticipate ArQule's share price to reach $6.75 in the next twelve months. This suggests a possible upside of 18.8% from the stock's current price. View Analyst Price Targets for ArQule.
What is the consensus analysts' recommendation for ArQule?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ArQule in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ArQule.
Who are some of ArQule's key competitors?
Some companies that are related to ArQule include Global Blood Therapeutics (GBT), Amicus Therapeutics (FOLD), Spectrum Pharmaceuticals (SPPI), Akorn (AKRX), Supernus Pharmaceuticals (SUPN), Myokardia (MYOK), Xencor (XNCR), Reata Pharmaceuticals (RETA), Cambrex (CBM), AnaptysBio (ANAB), Prestige Brands (PBH), Phibro Animal Health (PAHC), PTC Therapeutics (PTCT), Mirati Therapeutics (MRTX) and G1 Therapeutics (GTHX).
Who are ArQule's key executives?
ArQule's management team includes the folowing people:
- Mr. Paolo Pucci, CEO & Director (Age 57)
- Mr. Peter S. Lawrence J.D., Pres, COO & Sec. (Age 55)
- Mr. Robert J. Weiskopf, CFO & Treasurer (Age 67)
- Dr. Brian Schwartz, Chief Medical Officer (Age 56)
- Dawn Schottlandt, Sr. Director of Investor Relations & Corp. Communications
Has ArQule been receiving favorable news coverage?
News stories about ARQL stock have trended somewhat positive on Tuesday, Accern Sentiment reports. The research firm identifies positive and negative news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ArQule earned a news and rumor sentiment score of 0.13 on Accern's scale. They also gave news stories about the biotechnology company an impact score of 49.14 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days. View Recent Headlines for ArQule.
Who are ArQule's major shareholders?
ArQule's stock is owned by many different of institutional and retail investors. Top institutional investors include BIOTECHNOLOGY VALUE FUND L P (12.30%), BlackRock Inc. (4.95%), Millennium Management LLC (3.84%), Renaissance Technologies LLC (2.63%), Menora Mivtachim Holdings LTD. (2.26%) and Handelsbanken Fonder AB (0.73%). Company insiders that own ArQule stock include Paolo Pucci, Patrick J Zenner, Ran Nussbaum, Ronald M Lindsay and Value Fund L P Biotechnology. View Institutional Ownership Trends for ArQule.
Which institutional investors are selling ArQule stock?
ARQL stock was sold by a variety of institutional investors in the last quarter, including DAFNA Capital Management LLC and NJ State Employees Deferred Compensation Plan. View Insider Buying and Selling for ArQule.
Which institutional investors are buying ArQule stock?
ARQL stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Millennium Management LLC, Menora Mivtachim Holdings LTD., Handelsbanken Fonder AB, Opaleye Management Inc., Renaissance Technologies LLC, EAM Global Investors LLC and Bailard Inc.. Company insiders that have bought ArQule stock in the last two years include Paolo Pucci, Patrick J Zenner, Ran Nussbaum and Ronald M Lindsay. View Insider Buying and Selling for ArQule.
How do I buy shares of ArQule?
Shares of ARQL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ArQule's stock price today?
One share of ARQL stock can currently be purchased for approximately $5.68.
How big of a company is ArQule?
ArQule has a market capitalization of $682.28 million and generates $4.71 million in revenue each year. The biotechnology company earns $-29,200,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis. ArQule employs 32 workers across the globe.
How can I contact ArQule?
ArQule's mailing address is ONE WALL STREET, BURLINGTON MA, 01803. The biotechnology company can be reached via phone at 781-994-0300 or via email at [email protected]
MarketBeat Community Rating for ArQule (NASDAQ ARQL)
MarketBeat's community ratings are surveys of what our community members think about ArQule and other stocks. Vote "Outperform" if you believe ARQL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARQL will underperform the S&P 500 over the long term. You may vote once every thirty days.
